Sunday, August 01, 2021 2:29:08 PM
moneycrew - I don't use twitter and only spent a few minutes searching but the only reference to vacation (and no other to personal sabbatical that I can find) AF ever made was two years ago and for the standard two weeks off.
Maybe there are other occurrences folks are aware of but if not... a month off for someone who's role in life (as miserable and pathetic it is) hinges on projecting relevance by bombarding the ether with frequent and constant self-serving tweets and bottom of the barrel biotech analysis articles just does not sound kosher.
I've also read other notes from sages on this board that SEC and DOJ always investigate for a year + before taking action or making their action known. That's a heap of nonsense as the first order of priority for SEC and DOJ is to protect current and future investors and an immediate shut down or restriction in trading.
In the one case where I was directly affected (as an investor in a company that ultimately saw its leadership get charged and jailed) the SEC suspended trading (OTC BB stock) out of the blue, conducted an investigation for nearly 9 months (I was approached and chose to provide statements as an investor) and upon conclusion of the investigation charges were filed and the suspension became permanent.
I am personally very excited to see these investigations take place as its a win all around. If CytoDyn's leadership is actually guilty of any wrong doing - I will welcome any provable and reliable finding and associated actions. If this relates (as I suspect) to the criminal behavior that resulted in a totally unnatural trading profile over the past 12-15 months - watching anyone take a well-deserved beating over these activities and decoupling CytoDyn from the effects of the criminal cabal would be most satisfying.
Looking forward to these events unfolding!
Maybe there are other occurrences folks are aware of but if not... a month off for someone who's role in life (as miserable and pathetic it is) hinges on projecting relevance by bombarding the ether with frequent and constant self-serving tweets and bottom of the barrel biotech analysis articles just does not sound kosher.
I've also read other notes from sages on this board that SEC and DOJ always investigate for a year + before taking action or making their action known. That's a heap of nonsense as the first order of priority for SEC and DOJ is to protect current and future investors and an immediate shut down or restriction in trading.
In the one case where I was directly affected (as an investor in a company that ultimately saw its leadership get charged and jailed) the SEC suspended trading (OTC BB stock) out of the blue, conducted an investigation for nearly 9 months (I was approached and chose to provide statements as an investor) and upon conclusion of the investigation charges were filed and the suspension became permanent.
I am personally very excited to see these investigations take place as its a win all around. If CytoDyn's leadership is actually guilty of any wrong doing - I will welcome any provable and reliable finding and associated actions. If this relates (as I suspect) to the criminal behavior that resulted in a totally unnatural trading profile over the past 12-15 months - watching anyone take a well-deserved beating over these activities and decoupling CytoDyn from the effects of the criminal cabal would be most satisfying.
Looking forward to these events unfolding!
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
